Mark Rubinstein to Interleukin-2
This is a "connection" page, showing publications Mark Rubinstein has written about Interleukin-2.
Connection Strength
2.487
-
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
Score: 0.590
-
IL-2 and Beyond in Cancer Immunotherapy. J Interferon Cytokine Res. 2018 02; 38(2):45-68.
Score: 0.582
-
Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. Cancer Immunol Immunother. 2017 Jun; 66(6):737-751.
Score: 0.547
-
IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
Score: 0.498
-
An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. J Exp Med. 2007 Aug 06; 204(8):1787-801.
Score: 0.070
-
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9166-71.
Score: 0.065
-
Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006 Mar 31; 311(5769):1924-7.
Score: 0.064
-
Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine. 2003 Jun 02; 21(19-20):2318-28.
Score: 0.053
-
The lymphopenic environment of CD132 (common gamma-chain)-deficient hosts elicits rapid homeostatic proliferation of naive T cells via IL-15. J Immunol. 2008 Apr 15; 180(8):5320-6.
Score: 0.018